Quantcast

KemPharm, Inc. to Present at Biotech Showcase(TM) 2014

January 9, 2014

CORALVILLE, Iowa, Jan. 9, 2014 /PRNewswire/ — KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D. will present at the Biotech Showcase(TM) 2014 Conference being held in San Francisco January 13-15, 2014.

Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm’s development pipeline, including KP201, the company’s lead clinical candidate for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC).

Details of KemPharm’s presentation are as follows:

    Event:                      Biotech Showcase 2014
                                Conference

    Date:                      Wednesday, January 15, 2014

    Time:                      10:30 am, PST

    Location:                   Hearst Room -Parc 55
                                Wyndham San Francisco
                                Union Square Hotel

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases. KemPharm’s lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the third quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm’s pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD. For more information on KemPharm, please visit the company’s website at www.kempharm.com.

    For KemPharm, Inc: Media / Investor Contacts:

    Christal Mickle    Jason Rando / Joshua Drumm, Ph.D.

    319-665-2575       Tiberend Strategic Advisors, Inc.

    info@kempharm.com  212.827.0020

                       jrando@tiberend.com

                       jdrumm@tiberend.com

SOURCE KemPharm, Inc.


Source: PR Newswire



comments powered by Disqus